|Bid||223.09 x 800|
|Ask||228.00 x 800|
|Day's Range||223.62 - 230.31|
|52 Week Range||177.05 - 276.69|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||18.27|
|Earnings Date||Apr. 28, 2021 - May 03, 2021|
|Forward Dividend & Yield||7.04 (3.13%)|
|Ex-Dividend Date||Feb. 11, 2021|
|1y Target Est||254.24|
AstraZeneca and Amgen's experimental drug reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers. The medicine, tezepelumab, cut the rate of asthma attacks by 56% among patients when compared to placebo in a year-long late-stage study, which had roughly 1,000 patients who were already receiving standard care, the drugmakers said on Friday. It also worked in a subgroup of volunteers with low levels of eosinophils, a type of white blood cell, detailed data presented at a virtual meeting of the American Academy of Allergy Asthma and Immunology showed.
This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?
FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.